At Priothera, our vision is to extend and enhance the quality of life and radically transform the treatment of patients with hematological malignancies.
We are committed to pioneering innovative therapies that can enhance the curative potential of both allogeneic hematopoietic cell transplantation (allo-HCT) and CAR T cell therapy. Our goal is to deliver treatments that not only improve survival rates but also ensure safer and more effective long-term outcomes compared to today’s standard care.
The Impact of Acute Myeloid Leukemia
*From the American Cancer Society 2020
New estimated cases of leukemia (all kinds) in the US
New estimated cases of AML in the US
Estimated deaths from AML in the US
Priothera is exploring ways to address unmet medical needs in hematological malignancies by investigating innovative immune modulators that can enhance outcomes in allogeneic hematopoietic cell transplantation.
Through the development of our investigational drug, mocravimod, we aim to address critical challenges in current allo-HCT maintenance strategies by enhancing the graft-versus-leukemia (GvL) effect while simultaneously reducing graft-versus-host disease (GvHD).
Science
Hematopoietic Cell Transplantation (HCT)
Mocravimod
Our Pipeline
CAR T Cell Therapy
MO-TRANS Study
Leadership Statement
Florent Gros,
Founder, CEO of Priothera
“Applying mocravimod’s well-described mode of action to hematological malignancies will bring a game changing treatment to patients suffering from devastating blood cancers.”
Dhaval Patel,
Director, Former EU Research Head, Novartis
